p.47 抽出テキスト

August 1, 2017 Circulation. 2017;136:e60–e122. DOI: 10.1161/CIR.0000000000000499 e106

323.	 Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010;55:783–8. 324.	 Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003;14:337–41. 325.	 Ouriel K, Moss AJ. Long QT syndrome: an indication for cervicothoracic sympathectomy. Cardiovasc Surg. 1995;3:475–8. 326.	 Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826–33. 327.	 Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm. 2009;6:752–9. 328.	 Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512–9. 329.	 Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66–70. 330.	 Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196–200. 331.	Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001;103:485–90. 332.	 Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69:1378–84. 333.	 Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation. 2001;103:2822–7. 334.	 Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426–34. 335.	 Ackerman MJ, Zipes DP, Kovacs RJ, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66:2424–8. 336.	 Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69–74. 337.	 Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 2015;8:633–42. 338.	 van der Werf C, Zwinderman AH, Wilde AA.M. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace. 2012;14:175–83. 339.	 Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and longterm outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011;8:864–71. 340.	 van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244–54. 341.	 Padfield GJ, AlAhmari L, Lieve KV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade. Heart Rhythm. 2016;13: 609–13. 342.	 Moray A, Kirk EP, Grant P, et al. Prophylactic left thoracic sympathectomy to prevent electrical storms in CPVT patients needing ICD placement. Heart Lung Circ. 2011;20:731–3. 343.	 Celiker A, Erdoğan I, Karagöz T, et al. Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia. Cardiol Young. 2009;19:45–52. 344.	 Marai I, Khoury A, Suleiman M, et al. Importance of ventricular tachy-

cardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. Am J Cardiol. 2012;110:72–6. 345.	 Roses-Noguer F, Jarman JW.E, Clague JR, et al. Outcomes of defibrillator

therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11:58–66. 346.	 Swan H, Laitinen P, Kontula K, et al. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol. 2005;16:162–6. 347.	 Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:1149–54. 348.	 Wilde AA.M, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358:2024–9. 349.	 De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left ­cardiac sympathetic denervation. Circulation. 2015;131:2185–93. 350.	 Waddell-Smith KE, Ertresvaag KN, Li J, et al. Physical and psychological consequences of left cardiac sympathetic denervation for long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2015 351.	 Junttila MJ, Sager SJ, Freiser M, et al. Inferolateral early repolarization in athletes. J Interv Card Electrophysiol. 2011;31:33–8. 352.	 Haïssaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008;358:2016–23. 353.	 Rosso R, Kogan E, Belhassen B, et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol. 2008;52:1231–8. 354.	 Derval N, Simpson CS, Birnie DH, et al. Prevalence and characteristics of early repolarization in the CASPER registry: cardiac arrest survivors with preserved ejection fraction registry. J Am Coll Cardiol. 2011;58:722–8. 355.	 Abe A, Ikeda T, Tsukada T, et al. Circadian variation of late potentials in idiopathic ventricular fibrillation associated with J waves: insights into alternative pathophysiology and risk stratification. Heart Rhythm. 2010;7:675–82. 356.	 Merchant FM, Noseworthy PA, Weiner RB, et al. Ability of terminal QRS notching to distinguish benign from malignant electrocardiographic forms of early repolarization. Am J Cardiol. 2009;104:1402–6. 357.	 Sinner MF, Reinhard W, Müller M, et al. Association of early repolarization pattern on ECG with risk of cardiac and all-cause mortality: a population-based prospective cohort study (MONICA/KORA). PLoS Med. 2010;7:e1000314 358.	 Nunn LM, Bhar-Amato J, Lowe MD, et al. Prevalence of J-point elevation in sudden arrhythmic death syndrome families. J Am Coll Cardiol. 2011;58:286–90. 359.	 Mahida S, Derval N, Sacher F, et al. Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome. J Am Coll Cardiol. 2015;65:151–9. 360.	 Morady F, DiCarlo LA Jr, Baerman JM, et al. Comparison of coupling intervals that induce clinical and nonclinical forms of ventricular tachycardia during programmed stimulation. Am J Cardiol. 1986;57:1269–73. 361.	 Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation. 2000;102:2898–906. 362.	 Glick G, Yu PN. Hemodynamic changes during spontaneous vasovagal reactions. Am J Med. 1963;34:42–51. 363.	 Hargreaves AD, Muir AL. Lack of variation in venous tone potentiates vasovagal syncope. Br Heart J. 1992;67:486–90. 364.	 Manyari DE, Rose S, Tyberg JV, et al. Abnormal reflex venous function in patients with neuromediated syncope. J Am Coll Cardiol. 1996;27:1730–5. 365.	 Thomson HL, Atherton JJ, Khafagi FA, et al. Failure of reflex venoconstriction during exercise in patients with vasovagal syncope. Circulation. 1996;93:953–9. 366.	 Rose MS, Koshman ML, Spreng S, et al. The relationship between healthrelated quality of life and frequency of spells in patients with syncope. J Clin Epidemiol. 2000;53:1209–16. 367.	 Ganzeboom KS, Colman N, Reitsma JB, et al. Prevalence and triggers of syncope in medical students. Am J Cardiol. 2003;91:1006–8.A8 368.	 Serletis A, Rose S, Sheldon AG, et al. Vasovagal syncope in medical students and their first-degree relatives. Eur Heart J. 2006;27:1965–70. 369.	 Romme JJ, Reitsma JB, Black CN, et al. Drugs and pacemakers for vaso-

vagal, carotid sinus and situational syncope. Cochrane Database Syst Rev. 2011:CD004194.

Downloaded from http://ahajournals.org by on October 7, 2026